News | September 29, 2022

Stevanato Group Presents Their Recent Developments At Four Major Trade Shows

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment and delivery and diagnostic solutions for the pharmaceutical, biotechnology, and life science industries, will be exhibiting at four major international trade shows during the fall season to present its products and services for CMOs, CDMOs and pharma companies.

In the U.S., Stevanato Group will exhibit on October 18-19 at PDA Universe Of Pre-filled Syringes and Devices in Palm Springs, October 23-26 at Pack Expo in Chicago, and October 24-25 at PODD in Boston; in Europe, from November 1-3, Stevanato Group will be at CPhI Worldwide in Frankfurt.

Stevanato Group will present its integrated offering, including the latest developments in the drug containment solutions business, updates to the contract manufacturing and proprietary drug delivery devices offering, and opportunities related to Pharma 4.0 for its manufacturing equipment segment.

Events Highlights:

  • At PDA Universe of Pre-filled Syringes and Devices, Stevanato Group will present its integrated capabilities to offer contract manufacturing services for devices;
  • At Pack Expo, there will be a live demo of Stevanato Group's high-speed auto-injector assembly line; visitors will also be involved in the latest innovations and applications for digitization and pharma 4.0;
  • At PODD, the Group will delve into its recent collaboration with Owen Mumford for the Aidaptus® single-use auto-injector, explaining the technology behind this innovative device and how it can adapt to dry-fill volumes and primary containers;
  • At CPhI Worldwide, Stevanato Group, together with Gerresheimer AG, will officially launch the Ready-To-Use vial solution, recently presented to the press and based on Stevanato Group's market-leading EZ-fill® technology.
About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit:

Source: Stevanato Group